Difference between revisions of "Hainsworth JD, et al. Target Oncol. (2016) cited as Ref 633 in DOI: 10.1038/s41392-020-0110-5 (Q9896)"
Jump to navigation
Jump to search
(Created claim: title (P93): A randomized open-label phase 2 study of the CXCR4 inhibitor LY2510924 in combination with sunitinib versus sunitinib alone in patients with metastatic renal cell carcinoma (RCC), #quickstatements; #tempo...) |
(Created claim: Page(s) (P105): 643-653, #quickstatements; #temporary_batch_1590074839150) |
||
Property / Page(s) | |||
+ | 643-653 | ||
Property / Page(s): 643-653 / rank | |||
+ | Normal rank |
Latest revision as of 15:47, 21 May 2020
Cited in: "Targeting cancer stem cell pathways for cancer therapy" in Signal Transduct Target Ther; 2020 ; 5 8
Language | Label | Description | Also known as |
---|---|---|---|
English |
Hainsworth JD, et al. Target Oncol. (2016) cited as Ref 633 in DOI: 10.1038/s41392-020-0110-5
|
Cited in: "Targeting cancer stem cell pathways for cancer therapy" in Signal Transduct Target Ther; 2020 ; 5 8
|
Statements
Hainsworth JD
0 references
2016
0 references
Target Oncol.
0 references
11
0 references
A randomized open-label phase 2 study of the CXCR4 inhibitor LY2510924 in combination with sunitinib versus sunitinib alone in patients with metastatic renal cell carcinoma (RCC) (English)
0 references
643-653
0 references